Validity of Laboratory Biomarkers in Diagnosis of Nonalcoholic Fatty Liver Disease (NAFLD) and It's Consequences
- Sponsor
- Assiut University
- Study ID
- NCT06908122
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Non-alcoholic Fatty Liver Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 19 Years - 60 Years
- Healthy Volunteers
- Not accepted
Interventions
- laboratory biomarkers in the diagnosis of NAFLD disease — DIAGNOSTIC_TESTAll included patients will be assessed as follows: 1\. Questionnaire: different questionnaire variables extrapolated from study published by Xin Li, 2024, Bao et al., 2024 (8), (9).The questionnaire will be divided into six parts: First section includes demographic characteristics of patients as (name , age, gender, occupation, educational level and special habits) The second section includes chronic diseases-related questions and drug administration as if a patient were diagnosed with chronic disease, on treatment and drugs used. The third section for assessment of dietary lifestyle includes: nutrition adherence to Mediterranean will be assessed by a validated 17-item MedDiet adherence questionnaire, which all participants will answer. A score will be given for each met objective: 1 (compliance) or 0 (non-compliance). The counseling session will be about the Mediterranean diet program, and a brochure will be given to each patient.
Study Details
The validity of laboratory biomarkers in the diagnosis of NAFLD is still not established, and adherence to a healthy dietary lifestyle for those patients in our community is not well studied.
Key Dates
- First listed
- Apr 3, 2025
- Start date
- Apr 1, 2025
- Status verified
- Mar 2025
- Primary completion
- Apr 1, 2026
- Completion
- Apr 1, 2026
Study Design
- Enrollment
- 100 participants (estimated)
Primary Outcome Measure
Validity of lab biomarkers in the diagnosis of nonalcoholic fatty liver disease (NAFLD) and it's consequences in comparison with abdominal ultrasound and fibroscan. [ Time Frame: 1 year ]
Related Studies
- SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver DiseasePHASE2 · Not Yet Recruiting · Justin Ryder · Chicago, Illinois
- Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)PHASE2 · Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- The Olmsted NAFLD Epidemiology Study (TONES)Recruiting · Mayo Clinic · Rochester, Minnesota
- AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)Recruiting · AdventHealth Translational Research Institute · Orlando, Florida